+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CNS relapse in a low risk acute promyelocytic leukemia patient treated with ATRA-based regimen: is there a role for prophylactic CNS therapy in acute promyelocytic leukemia?



CNS relapse in a low risk acute promyelocytic leukemia patient treated with ATRA-based regimen: is there a role for prophylactic CNS therapy in acute promyelocytic leukemia?



Indian Journal of Hematology and Blood Transfusion 25(3): 118-119



Though the incidence of CNS relapse in acute promyelocytic leukemia (AML-M3 FAB classification) has increased following the advent of all-trans retinoic acid (ATRA), still CNS relapse accounts for only 2-3% of all relapses in AML-M3 trated with standard ATRA plus chemotherapy regimen. We report a case of low risk AML-M3 treated with standard therapy, developing CNS relapse while on maintenance therapy with ATRA + 6-mercaptopurine (6-MP) + methotrexate (MTX).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051895020

Download citation: RISBibTeXText

PMID: 23100988

DOI: 10.1007/s12288-009-0024-4


Related references

High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen. Journal of Hematopathology 11(3): 67-74, 2018

Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. American Journal of Hematology 90(9): E181-E182, 2015

Central nervous system involvement at second relapse in acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia Research 34(10): E264-E265, 2010

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Annals of Hematology 93(12): 2001-2010, 2015

Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Annals of Hematology 78(7): 329-332, 1999

Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. Haematologica 96(9): 1390-1391, 2012

Extramedullary relapse following allogeneic stem cell transplantation in acute promyelocytic leukemia: the role of ATRA. Haematologica 86(10): E31, 2001

Factors Affecting Early Death and Survival of Patients With Acute Promyelocytic Leukemia Treated With ATRA-Based Therapy Regimens. Clinical Lymphoma, Myeloma & Leukemia 19(1): E63-E70, 2019

ATRA followed by chemotherapy vs ATRA plus CT, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia Results of APL 93 trial. Annals of Hematology 78(SUPPL 2): S14, 1999

Pharmacokinetic study of ATRA and the intermittent and cyclic regimen with ATRA and chemotherapy in pediatric acute promyelocytic leukemia. Blood 90(10 SUPPL 1 PART 2): 245B, Nov 15, 1997

ATRA followed by chemotherapy vs ATRA plus CT and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia First interim results of APL 93 trial. Blood 90(10 SUPPL 1 PART 1): 122A, Nov 15, 1997

Pituitary relapse of acute promyelocytic leukemia after ATRA. International Journal of Hematology 68(1): 101-102, 1998

Management of acute promyelocytic leukemia relapse in the ATRA era. Haematologica 83(8): 714-717, 1998

Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol. Revista Brasileira de Hematologia E Hemoterapia 38(4): 285-290, 2016

Treatment results of intermittent and cyclic regimen with ATRA and chemotherapy in childhood acute promyelocytic leukemia. Children's Cancer and Leukemia Study Group. Japanese Journal of Clinical Hematology 38(11): 1177-1182, 1998